Axovant Sciences Ltd
Most Recent
What Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
Audentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
Analyzing Axovant Sciences’ Valuation Metrics
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”
Investors Still Excited about Axovant
Axovant is focusing on gene therapy candidates AXO-Lenti-PD and AXO-AAV-OPMD.
Axovant and Benitec Biopharma Up on Gene Therapy Development Deal
Today, Axovant Sciences (AXON) registered a stock price rise of over 3.0%, and Australian firm Benitec Biopharma’s (BNTC) stock rose ~57.0%.
A Look at Axovant Sciences’ Therapy for Parkinson’s Disease
Axovant Sciences (AXON) and Oxford Biomedical aim to develop AXO-Lenti-PD gene therapy as a long-term treatment for PD (Parkinson’s disease).
Why Axovant Sciences Stock Is Soaring
Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80.
Why Axovant Sciences Stock Rose in Week Ended June 8
On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.
Why Axovant Sciences Stock Jumped ~160% on Wednesday
Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.
